Tradeshow News
Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT
From
To
Earnings Projects Or Forecasts
Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Fda Approval
Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settings
Conference Call Announcements
SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
Clinical Trials Medical Discoveries
Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument
Clinical Trials Medical Discoveries
PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India
Personnel Announcements
SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX)Â ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").
New Products Services
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner
New Products Services
More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs
Health Care Hospitals
Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week
